FGP
PRCT icon

Freestone Grove Partners’s Procept Biorobotics PRCT Stock Holding History

Freestone Grove Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,537
Closed -$483K – 898
2025
Q3 		$483K Buy
+13,537
New +$618K ﹤0.01% 541
2025
Q1 		– Sell
-2,575
Closed -$207K – 747
2024
Q4 		$207K Buy
+2,575
New +$220K ﹤0.01% 530

Other funds holding PRCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Freestone Grove Partners's PRCT Position: Q4 2025 in Review

Freestone Grove Partners sold out of Procept Biorobotics (PRCT) in Q4 2025, closing a stake of 13,537 shares — an estimated $483K sold.

Freestone Grove Partners first reported a position in PRCT in Q4 2024 and held it in 2 quarters. The position peaked at $483K in Q3 2025. 263 funds tracked by Wall St. Rank hold PRCT as of Q4 2025.

  • Freestone Grove Partners reported no remaining Procept Biorobotics position as of Q4 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 13,537 Procept Biorobotics shares in Q4 2025, an estimated $483K.
  • Freestone Grove Partners first reported a position in Procept Biorobotics in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's Procept Biorobotics position peaked at $483K in Q3 2025.
  • 263 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.